BRICANYL TURBOHALER

5mg) as required. Not more than 4 inhalations should be required in any 24-hour period. The duration of action of a single dose is up to 6 hours.

Elderly:

Dosage as for adults. Method of administration Instructions for use and cleaning are provided in the Patient Information Leaflet, which can be found in each pack.

Summary of the safety profile The frequency of adverse reactions is low at the recommended dose. Terbutaline given by inhalation is unlikely to produce significant systemic effects when given in recommended doses. Most of the adverse reactions are characteristic of sympathomimetic amines.

The majority of these effects have reversed spontaneously within the first 1-2 weeks of treatment. The frequency of side effects is low at the recommended doses. Bricanyl Turbohaler inhalation powder contains lactose. The excipient lactose may contain small amounts of milk protein residues.

In patients with hypersensitivity to milk proteins, these small amounts may cause allergic reactions. Tabulated list of adverse reactions Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (>1/10), common (>1/100 and <1/10), uncommon (>1/1,000 and <1/100), rare (>1/10,000 and <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).

g. 4) Vascular Disorders Not Known ^ Peripheral vasodilation Respiratory, Thoracic and Mediastinal Disorders Not Known ^ Paradoxical bronchospasm * Gastrointestinal Disorders Not Known ^ Nausea Mouth and throat irritation Skin and Subcutaneous Tissue Disorders Not Known ^ Urticaria Rash Musculoskeletal and Connective Tissue Disorders # Common (>1/100 to <1/10) Muscle spasms # A few patients feel tense; this is also due to the effects on skeletal muscle and not to direct CNS stimulation.

^ Reported spontaneously in post-marketing data and therefore frequency regarded as not known * In rare cases, through unspecified mechanisms, paradoxical bronchospasm may occur, with wheezing immediately after inhalation. This should be immediately treated with a rapid-onset bronchodilator.

Bricanyl therapy should be discontinued and after assessment, an alternative therapy initiated. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Patients should be instructed in proper use and their inhalation technique checked regularly. With each inhalation a fraction of the delivered dose will be deposited in the oral cavity. To minimize unnecessary systemic exposure to terbutaline, the patients should be advised to, when possible, rinse their mouth after each use.

Patients who are prescribed regular anti-inflammatory therapy should be advised to continue taking their anti-inflammatory medication even when symptoms decrease and they do not require Bricanyl Turbohaler. If a previously effective dosage regimen no longer gives the same symptomatic relief, the patient should seek medical advice as soon as possible as this could be a sign of worsening asthma and warrants a reassessment of the asthma therapy.

Consideration should be given to the requirements for additional therapy (including increased dosages of anti-inflammatory medication). Severe exacerbations of asthma should be treated as an emergency in the usual manner. Overuse of short-acting beta-agonists may mask the progression of the underlying disease and contribute to deteriorating asthma control, leading to an increased risk of severe asthma exacerbations and mortality.

Patients who take more than twice a week additional “as needed” terbutaline should be re-evaluated for proper treatment adjustment as these patients are at risk for overuse of terbutaline. As for all beta2-agonists caution should be observed in patients with thyrotoxicosis.

Due to the positive inotropic effect of beta2-agonists, these drugs should not be used in patients with hypertrophic cardiomyopathy. Cardiovascular effects may be seen with sympathomimetic drugs, including Bricanyl. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with beta agonists.

g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving Bricanyl should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin.

Due to the hyperglycaemic effects of beta2-agonists, additional blood glucose controls are recommended initially in diabetic patients. Potentially serious hypokalaemia may result from beta2-agonist therapy. Particular caution is recommended in acute severe asthma as the associated risk may be augmented by hypoxia.

5). It is recommended that serum potassium levels are monitored in such situations. Bricanyl Turbohaler contains lactose monohydrate (<1 mg/inhalation). This amount does not normally cause problems in lactose intolerant people. The lactose may contain small amounts of milk protein residues.

In patients with hypersensitivity to milk proteins, these small amounts may cause allergic reactions. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

1.